Pilot ex-vivo investigation of an experimental beta probe for assessment and guidance of prostate cancer resection
68Ga-PSMA is a radiopharmaceutical used with PET imaging for the detection of prostate cancer under a compassionate IND in patients who have presented with biochemical failure. In this study, the use of 68Ga-PSMA-11 will be extended to newly diagnosed patients with high risk prostate cancer. Patients enrolled to this study will undergo a 68Ga-PSMA-11 PET/CT or PET/MRI scan for research purposes (in addition to the routine CT or MRI that is routinely done for staging), and a second 68Ga-PSMA-11 administration just prior to surgery for experimental ex-vivo beta probe testing of resected tissue. Immediately following resection of the prostate, the intact tissue will be scanned using a PET camera designed for animal research in order to record the 68Ga-PSMA-11 distribution in the isolated tissue at higher resolution than can be attained using whole-body PET imaging. The experimental beta probe will then be use to measure 68Ga-PSMA-11 counts of the resected tissue.
The purpose of this study is to assess beta ray detection of prostate cancer ex-vivo using an experimental beta probe immediately after prostate cancer removal.
- IRB Number: 1703641238 (IUSCC-0615)
- Research Study Identifier: TX7913
- Principal Investigator: Clinton Bahler, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required